Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
Garcia-Guiñon, A. (Hospital Universitari Arnau de Vilanova)
Charry, Paola (Hospital Clínic i Provincial de Barcelona)
Jimenez, María (Hospital Universitari Vall d'Hebron)
Sarra, J. (Hospital Universitari Joan XXIII- ICO Camp de Tarragona)
Delgado, I. (Hospital Universitari Arnau de Vilanova)
Segura de la Torre, Laura (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Santaliestra, M. (Hospital Universitari MútuaTerrassa)
Garcia-Pintos, M. (Consorci Sanitari de Terrassa)
Gonzalez, Y. (Hospital Universitari Josep Trueta-ICO Girona)
Senin, Alicia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Motlló, C. (Hospital Sant Joan de Déu - Fundació Althaia)
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya))
Cabezudo, E. (Hospital St Joan Despi-Moises Broggi-ICO-H)
Granell, Miquel (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Sancho, E. (Hospital General de Granollers)
Herranz, M.J. (Hospital del Vendrell - Xarxa Santa Tecla)
Seres, Y. (Hospital Universitari Arnau de Vilanova)
Gironella, Mercedes (Hospital Universitari Vall d'Hebron)
Soler, Juan Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Marti-Tutusaus, J.M. (Hospital Universitari MútuaTerrassa)
Ben Azaiz, Ran (Hospital del Mar (Barcelona, Catalunya))
Fernández de Larrea, Carlos (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Carfilzomib ; Lenalidomide and dexamethasone ; Real-world ; Relapsed/refractory multiple myeloma
Published in:	Annals of hematology, Vol. 104 Núm. 2 (february 2025) , p. 1177-1186, ISSN 1432-0584

DOI: 10.1007/s00277-025-06240-1
PMID: 39954075

10 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles